Pathology review for paediatric non-Hodgkin's lymphoma patients in Japan

A report from the Japan association of childhood leukaemia study (JACLS)

A. Nakagawa, S. Nakamura, H. Nakamine, Tadashi Yoshino, T. Takimoto, K. Horibe, K. Ueda

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A central pathology review system with an immunophenotyping laboratory was established in Japan to support the clinical trial, the Japan Association of Childhood Leukaemia Study (JACLS) NHL-98, for patients with paediatric non-Hodgkin's lymphoma (NHL). Pathology samples from 155 clinically-suspected NHL cases were evaluated centrally initially using the Revised European-American Lymphoma (REAL) classification in a rapid review (within 2 weeks after surgery/biopsy) and then later at the consensus review (once a year). The samples were subsequently re-classified according to the new World Health Organisation (WHO) classification. After the pathology review, 96 (62%) patients were eligible for the study, and 58 of them (60%) had extra-nodal primaries. These NHL cases included B-cell lymphomas (precursor B-cell, 11; Burkitt, 18; diffuse large B-cell, 18; not otherwise specified, 3) and T/ Natural Killer (NK)-cell lymphomas (precursor T-cell, 23; anaplastic large cell, 20; others, 3). There was excellent concordance in making the diagnoses (95/96, 99%) and typing (93/96, 97%) of NHL between the rapid and consensus reviews. Five cases, initially diagnosed as diffuse large B-cell lymphoma by the review, were re-classified as Burkitt lymphoma according to the immunocytochemical criteria by the WHO classification. A total of 59 (38%) cases were excluded from the study: they were Hodgkin lymphoma (7), leukaemias (11), reactive lymphoid hyperplasia (20), necrotizing lymphadenitis (7), no consensus diagnosis (1), insufficient materials (2), and others (11). This is the first report of the central pathology review from the paediatric NHL group study in Japan. Because various diseases, either neoplastic or reactive, mimicked NHL, clinically and histopathologically, the central pathology review system was critical and essential for patient enrollment and protocol assignment in our clinical trial. Through the two-step review system, highly reliable data were generated to support this study.

Original languageEnglish
Pages (from-to)725-733
Number of pages9
JournalEuropean Journal of Cancer
Volume40
Issue number5
DOIs
Publication statusPublished - Mar 2004

Fingerprint

Non-Hodgkin's Lymphoma
Japan
Leukemia
Pediatrics
Pathology
Clinical Trials
Pseudolymphoma
T-Lymphoid Precursor Cells
Immunophenotyping
Lymphadenitis
Natural Killer T-Cells
B-Lymphoid Precursor Cells
Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
T-Cell Lymphoma
B-Cell Lymphoma
Hodgkin Disease
Lymphoma
B-Lymphocytes
Biopsy

Keywords

  • Central review
  • Group study
  • Japanese children
  • Non-Hodgkin's lymphoma
  • Pathology
  • WHO classification

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Pathology review for paediatric non-Hodgkin's lymphoma patients in Japan : A report from the Japan association of childhood leukaemia study (JACLS). / Nakagawa, A.; Nakamura, S.; Nakamine, H.; Yoshino, Tadashi; Takimoto, T.; Horibe, K.; Ueda, K.

In: European Journal of Cancer, Vol. 40, No. 5, 03.2004, p. 725-733.

Research output: Contribution to journalArticle

@article{e1137a8446504592bfd5dcc650588ad0,
title = "Pathology review for paediatric non-Hodgkin's lymphoma patients in Japan: A report from the Japan association of childhood leukaemia study (JACLS)",
abstract = "A central pathology review system with an immunophenotyping laboratory was established in Japan to support the clinical trial, the Japan Association of Childhood Leukaemia Study (JACLS) NHL-98, for patients with paediatric non-Hodgkin's lymphoma (NHL). Pathology samples from 155 clinically-suspected NHL cases were evaluated centrally initially using the Revised European-American Lymphoma (REAL) classification in a rapid review (within 2 weeks after surgery/biopsy) and then later at the consensus review (once a year). The samples were subsequently re-classified according to the new World Health Organisation (WHO) classification. After the pathology review, 96 (62{\%}) patients were eligible for the study, and 58 of them (60{\%}) had extra-nodal primaries. These NHL cases included B-cell lymphomas (precursor B-cell, 11; Burkitt, 18; diffuse large B-cell, 18; not otherwise specified, 3) and T/ Natural Killer (NK)-cell lymphomas (precursor T-cell, 23; anaplastic large cell, 20; others, 3). There was excellent concordance in making the diagnoses (95/96, 99{\%}) and typing (93/96, 97{\%}) of NHL between the rapid and consensus reviews. Five cases, initially diagnosed as diffuse large B-cell lymphoma by the review, were re-classified as Burkitt lymphoma according to the immunocytochemical criteria by the WHO classification. A total of 59 (38{\%}) cases were excluded from the study: they were Hodgkin lymphoma (7), leukaemias (11), reactive lymphoid hyperplasia (20), necrotizing lymphadenitis (7), no consensus diagnosis (1), insufficient materials (2), and others (11). This is the first report of the central pathology review from the paediatric NHL group study in Japan. Because various diseases, either neoplastic or reactive, mimicked NHL, clinically and histopathologically, the central pathology review system was critical and essential for patient enrollment and protocol assignment in our clinical trial. Through the two-step review system, highly reliable data were generated to support this study.",
keywords = "Central review, Group study, Japanese children, Non-Hodgkin's lymphoma, Pathology, WHO classification",
author = "A. Nakagawa and S. Nakamura and H. Nakamine and Tadashi Yoshino and T. Takimoto and K. Horibe and K. Ueda",
year = "2004",
month = "3",
doi = "10.1016/j.ejca.2003.09.039",
language = "English",
volume = "40",
pages = "725--733",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Pathology review for paediatric non-Hodgkin's lymphoma patients in Japan

T2 - A report from the Japan association of childhood leukaemia study (JACLS)

AU - Nakagawa, A.

AU - Nakamura, S.

AU - Nakamine, H.

AU - Yoshino, Tadashi

AU - Takimoto, T.

AU - Horibe, K.

AU - Ueda, K.

PY - 2004/3

Y1 - 2004/3

N2 - A central pathology review system with an immunophenotyping laboratory was established in Japan to support the clinical trial, the Japan Association of Childhood Leukaemia Study (JACLS) NHL-98, for patients with paediatric non-Hodgkin's lymphoma (NHL). Pathology samples from 155 clinically-suspected NHL cases were evaluated centrally initially using the Revised European-American Lymphoma (REAL) classification in a rapid review (within 2 weeks after surgery/biopsy) and then later at the consensus review (once a year). The samples were subsequently re-classified according to the new World Health Organisation (WHO) classification. After the pathology review, 96 (62%) patients were eligible for the study, and 58 of them (60%) had extra-nodal primaries. These NHL cases included B-cell lymphomas (precursor B-cell, 11; Burkitt, 18; diffuse large B-cell, 18; not otherwise specified, 3) and T/ Natural Killer (NK)-cell lymphomas (precursor T-cell, 23; anaplastic large cell, 20; others, 3). There was excellent concordance in making the diagnoses (95/96, 99%) and typing (93/96, 97%) of NHL between the rapid and consensus reviews. Five cases, initially diagnosed as diffuse large B-cell lymphoma by the review, were re-classified as Burkitt lymphoma according to the immunocytochemical criteria by the WHO classification. A total of 59 (38%) cases were excluded from the study: they were Hodgkin lymphoma (7), leukaemias (11), reactive lymphoid hyperplasia (20), necrotizing lymphadenitis (7), no consensus diagnosis (1), insufficient materials (2), and others (11). This is the first report of the central pathology review from the paediatric NHL group study in Japan. Because various diseases, either neoplastic or reactive, mimicked NHL, clinically and histopathologically, the central pathology review system was critical and essential for patient enrollment and protocol assignment in our clinical trial. Through the two-step review system, highly reliable data were generated to support this study.

AB - A central pathology review system with an immunophenotyping laboratory was established in Japan to support the clinical trial, the Japan Association of Childhood Leukaemia Study (JACLS) NHL-98, for patients with paediatric non-Hodgkin's lymphoma (NHL). Pathology samples from 155 clinically-suspected NHL cases were evaluated centrally initially using the Revised European-American Lymphoma (REAL) classification in a rapid review (within 2 weeks after surgery/biopsy) and then later at the consensus review (once a year). The samples were subsequently re-classified according to the new World Health Organisation (WHO) classification. After the pathology review, 96 (62%) patients were eligible for the study, and 58 of them (60%) had extra-nodal primaries. These NHL cases included B-cell lymphomas (precursor B-cell, 11; Burkitt, 18; diffuse large B-cell, 18; not otherwise specified, 3) and T/ Natural Killer (NK)-cell lymphomas (precursor T-cell, 23; anaplastic large cell, 20; others, 3). There was excellent concordance in making the diagnoses (95/96, 99%) and typing (93/96, 97%) of NHL between the rapid and consensus reviews. Five cases, initially diagnosed as diffuse large B-cell lymphoma by the review, were re-classified as Burkitt lymphoma according to the immunocytochemical criteria by the WHO classification. A total of 59 (38%) cases were excluded from the study: they were Hodgkin lymphoma (7), leukaemias (11), reactive lymphoid hyperplasia (20), necrotizing lymphadenitis (7), no consensus diagnosis (1), insufficient materials (2), and others (11). This is the first report of the central pathology review from the paediatric NHL group study in Japan. Because various diseases, either neoplastic or reactive, mimicked NHL, clinically and histopathologically, the central pathology review system was critical and essential for patient enrollment and protocol assignment in our clinical trial. Through the two-step review system, highly reliable data were generated to support this study.

KW - Central review

KW - Group study

KW - Japanese children

KW - Non-Hodgkin's lymphoma

KW - Pathology

KW - WHO classification

UR - http://www.scopus.com/inward/record.url?scp=1542329051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542329051&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2003.09.039

DO - 10.1016/j.ejca.2003.09.039

M3 - Article

VL - 40

SP - 725

EP - 733

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -